CYP46A1 and Alzheimer disease: In summary, to further characterize EFV as an anti-AD therapeutic and to identify more potent in vivo activators of CYP46A1 than EFV, we focused on 8,14-dihydroxyEFV, the phase 1 minor metabolite of EFV.